TrialThe New England journal of medicine2017
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Kenneth I Ataga et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
465 papers cite itlatest 60 shown
this paperpooled ittrialcites it